Business Description
Arctic Bioscience AS
ISIN : NO0010859580
Compare
Compare
Traded in other countries / regions
ABS.Norway9TD.Germany IPO Date
2021-02-24Description
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. The company is developing a novel, oral drug candidate (HRO350) for the treatment of mild-to-moderate psoriasis. The company operates geographically in Norway, Americas, Europe, and APAC, with majority of the revenue deriving from Europe.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.83 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.4 | |||||
| Beneish M-Score | -2.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.7 | |||||
| 3-Year EBITDA Growth Rate | 1.4 | |||||
| 3-Year EPS without NRI Growth Rate | -2.6 | |||||
| 3-Year FCF Growth Rate | -6.7 | |||||
| 3-Year Book Growth Rate | -14.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.46 | |||||
| 9-Day RSI | 56.44 | |||||
| 14-Day RSI | 54.63 | |||||
| 3-1 Month Momentum % | -24.13 | |||||
| 6-1 Month Momentum % | 14.05 | |||||
| 12-1 Month Momentum % | -66.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.86 | |||||
| Quick Ratio | 0.43 | |||||
| Cash Ratio | 0.03 | |||||
| Days Inventory | 355.83 | |||||
| Days Sales Outstanding | 99.6 | |||||
| Days Payable | 218.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | -13.22 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 27.34 | |||||
| Operating Margin % | -109.91 | |||||
| Net Margin % | -110.23 | |||||
| EBITDA Margin % | -91.15 | |||||
| FCF Margin % | -221.17 | |||||
| ROE % | -20.41 | |||||
| ROA % | -16.85 | |||||
| ROIC % | -20.6 | |||||
| 3-Year ROIIC % | -4.45 | |||||
| ROC (Joel Greenblatt) % | -136.88 | |||||
| ROCE % | -18.93 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 2.46 | |||||
| PS Ratio | 2.21 | |||||
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 7.15 | |||||
| EV-to-EBIT | -2.95 | |||||
| EV-to-EBITDA | -3.35 | |||||
| EV-to-Revenue | 3.05 | |||||
| EV-to-FCF | -1.3 | |||||
| Price-to-GF-Value | 0.2 | |||||
| Earnings Yield (Greenblatt) % | -33.86 | |||||
| FCF Yield % | -94.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arctic Bioscience AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 43.483 | ||
| EPS (TTM) (kr) | -1.892 | ||
| Beta | 2.52 | ||
| 3-Year Sharpe Ratio | -0.01 | ||
| 3-Year Sortino Ratio | -0.02 | ||
| Volatility % | 140.17 | ||
| 14-Day RSI | 54.63 | ||
| 14-Day ATR (kr) | 0.381737 | ||
| 20-Day SMA (kr) | 3.617 | ||
| 12-1 Month Momentum % | -66.44 | ||
| 52-Week Range (kr) | 1.65 - 16.8 | ||
| Shares Outstanding (Mil) | 26.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arctic Bioscience AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arctic Bioscience AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arctic Bioscience AS Frequently Asked Questions
What is Arctic Bioscience AS(OSL:ABS)'s stock price today?
The current price of OSL:ABS is kr3.79. The 52 week high of OSL:ABS is kr16.80 and 52 week low is kr1.65.
When is next earnings date of Arctic Bioscience AS(OSL:ABS)?
The next earnings date of Arctic Bioscience AS(OSL:ABS) is 2025-08-28.
Does Arctic Bioscience AS(OSL:ABS) pay dividends? If so, how much?
Arctic Bioscience AS(OSL:ABS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers